

Feedback Requested: pCODR Transition Stakeholder Consultation Report

July 23, 2014

Hello,

I am pleased to provide a first draft of the [report](#) generated from stakeholder consultations on the transfer of pCODR to CADTH.

The [report](#) summarizes the results of the survey we issued in May 2014 and the key points, questions, and comments from the Stakeholder Information Sessions held on June 9, 2014. We would appreciate knowing if you feel the report accurately reflects the key issues that have been raised to date. If you have any other suggestions or thoughts about the transfer, we would be pleased to receive these as well.

In addition to general feedback on the [report](#), we would value your input on a few other questions:

1. Did you find the information sessions helpful in addressing your questions regarding the transfer of pCODR to CADTH?
2. Some stakeholders are familiar with the CADTH Common Drug Review (CDR). For those who are, what do you consider to be some of the best practices of pCODR and CDR that we should continue to build on? Please list and provide examples, as applicable.
3. During the information sessions, there were suggestions to increase the transparency of the review process — for example, by making pCODR Expert Review Committee (pERC) meetings public and by allowing patient groups and pharmaceutical companies to present, in person, at committee meetings. Increasing transparency could require additional resources, which could impact timelines and result in the limited use of certain confidential and proprietary information (which, in turn, could impact pERC's ability to deliberate).
 - a) Would you like to see increased transparency in the pCODR process?
 - b) If so, would you be willing to accept trade-offs? Please explain.

Please email your written feedback to info@pcodr.ca by **September 16, 2014 at 5:00pm ET** using our [template](#).

I look forward to hearing from you.

Regards,

Mona Sabharwal
Executive Director, pCODR